Organization · Venture Capital
Longitude Capital
Longitude Capital is a venture capital firm based in Menlo Park, California, and Boston, Massachusetts, specializing in venture growth investments in biotechnology, medical technology, and health solutions companies.
Overview
What Longitude Capital does
What Longitude Capital is
Longitude Capital is a venture capital firm based in Menlo Park, California, and Boston, Massachusetts, specializing in venture growth investments in biotechnology, medical technology, and health solutions companies.
How it participates in the startup ecosystem
The current public profile supports funder capabilities. Each capability below is shown separately so organization identity and role-specific information do not get conflated.
Operational profile
Organization status and context
Organization status describes the entity itself. Funding and program availability appear within the relevant capability profile.
- Operational status
- Active
- Organization type
- Venture Capital
- Founded
- Founded in 2006
- Approximate age
- About 20 years
- Structured capabilities
- Funder
- Last reviewed
- March 18, 2026
Official channels
Find Longitude Capital elsewhere
Open the official website or a supported primary organization account.
Capability profile
Longitude Capital as a funder
Investment thesis
Longitude Capital focuses on venture growth investments in transformative healthcare companies, emphasizing biotechnology, medical technology, and health solutions with clinically de-risked assets.
Focus narrative
Longitude Capital invests in both privately held and publicly traded companies within the healthcare sector. Their strategy includes a balanced portfolio of clinical-stage and commercial-stage companies, employing various investment structures such as traditional venture capital, asset spin-outs, recapitalizations, PIPEs, and royalties. The firm leverages a broad network of industry relationships and proprietary thematic research to identify new investment opportunities.
Value beyond capital
Longitude Capital adds value to its portfolio companies through its extensive industry relationships, thematic research, and expertise in managing clinical-stage and commercial-stage investments. The firm supports its companies in navigating market challenges and optimizing growth strategies.
Focus and fit
- Stages
- Pre-seed · Seed · Seed+ · Series A · Series B · Series C · Growth Equity
- Sectors
- Biotech · Healthcare · Medical Devices · Health Data · Health Platforms
- Regions
- Global · North America
Availability
- Currently deploying
- Yes
Portfolio and track record
- Recorded portfolio count
- 75
- Recorded notable exits
- Aimmune Therapeutics and Bolt Medical
Portfolio context
Longitude Capital has invested in notable companies including Aimmune Therapeutics (founding Series A investor, IPO 2015, acquired by Nestle for $2.6B), Bolt Medical (acquired by Boston Scientific), Ceribell, Endogenex, Nalu Medical, RxSight, Sydnexis, BioAge Labs, CuraSen Therapeutics, Endeavor Biomedicines, Epirium Bio, Jazz Pharmaceuticals, Opna Bio, Orbus Therapeutics, Vera Therapeutics, Veradermics, and Zenas BioPharma.
Common questions
What to know about Longitude Capital
Upseed classifies Longitude Capital under the Venture Capital organization type. Its current public profile includes funder capabilities.
Source and update disclosure
Know what this page is based on
Source basis
Public organization and program material, official websites, and structured Upseed records.
Last reviewed
March 18, 2026
Known limits
Capability profiles appear only when a structured public profile also contains decision-useful role evidence. Terms and availability can change.
Upseed is an independent guide. It is not affiliated with or endorsed by the organization described on this page.